Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Nanorobots Could Redefine Targeted Cancer Therapies

XTALKS VITALS NEWS

These researchers have designed nanorobots capable of being injected into a patient’s bloodstream, and delivering a drug directly into cancerous cells.

Tweetables from this article:

Tweet: Nanorobot drug delivery could ensure that only the cancer cells are targeted by the drug http://ctt.ec/1U5yU+Nanorobot drug delivery could ensure that only the cancer cells are targeted by the drug.

Tweet: Nanorobots are able to enter a tumor and autonomically identify the hypoxic zones in tumors http://ctt.ec/O71IT+Nanorobots are able to enter a tumor and autonomically identify the hypoxic zones in tumors.

Share this!

August 17, 2016 | by Sarah Massey, M.Sc.

Targeting tumors using nanorobots could be the future of cancer treatment thanks to research performed at Polytechnique Montréal, Université de Montréal and McGill University. These researchers have designed nanorobots capable of being injected into a patient’s bloodstream, and delivering a drug directly into cancerous cells.

As many chemotherapeutic drugs used today are both cytotoxic to tumor cells and the surrounding healthy tissue, this mode of drug delivery could ensure that only the cancer cells are targeted by the drug. The researchers also believe that these nanorobot agents could reduce the effective dosage necessary, thereby further reducing toxic side-effects of the cancer therapies.

The research – published in the journal, Nature Nanotechnology – was conducted on mice with colorectal tumors. They found that the nanorobots were successful at delivering cancer drugs into the heart of the tumors.

“These legions of nanorobotic agents were actually composed of more than 100 million flagellated bacteria – and therefore self-propelled – and loaded with drugs that moved by taking the most direct path between the drug's injection point and the area of the body to cure,” said Professor Sylvain Martel, the senior author on the paper and holder of the Canada Research Chair in Medical Nanorobotics and Director of the Polytechnique Montréal Nanorobotics Laboratory. “The drug's propelling force was enough to travel efficiently and enter deep inside the tumors.”



One of the most significant challenges in cancer treatment today is in the delivery of drugs into the low-oxygen areas of the tumor, known as hypoxic zones. These areas are caused by increased consumption of oxygen by rapidly dividing tumor cells, and treatments like radiotherapy are ineffective against these hypoxic zones.

The nanorobots on the other hand, are able to enter a tumor and autonomically identify the hypoxic zones. They then release their drug load, essentially destroying the tumor from the inside out.

The nanorobots are able to navigate using a chain of magnetic nanoparticles which attracts them toward a magnetic field. In addition, an oxygen measuring sensor allows the nanotech bacteria to seek out the tumor’s hypoxic zones and remain there.

“This innovative use of nanotransporters will have an impact not only on creating more advanced engineering concepts and original intervention methods, but it also throws the door wide open to the synthesis of new vehicles for therapeutic, imaging and diagnostic agents,” said Martel. “Chemotherapy, which is so toxic for the entire human body, could make use of these natural nanorobots to move drugs directly to the targeted area, eliminating the harmful side effects while also boosting its therapeutic effectiveness.”


Keywords: Nanotechnology, Cancer, Chemotherapy


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Avastin Biosimilar Becomes First FDA-Approved Copy-Cat for Cancer

September 18, 2017 - In an historic event, the US Food and Drug Administration (FDA) has approved a biosimilar version of Roche’s cancer treatment Avastin (bevacizumab).

Featured In: Biotech News


Will an Open-Access Clinical Trials Database Improve Drug Development?

September 18, 2017 - New Jersey-based business intelligence firm OZMOSI has launched a free-to-use, open-access database of clinical trial data collected from studies around the world.

Featured In: Clinical Trial News


First Oral Drug for Type 1 Diabetes Could be Available in 2018

September 15, 2017 - A type 1 diabetes drug being codeveloped by Lexicon Pharmaceuticals and Sanofi could be the first oral treatment approved for the autoimmune disease following the release of promising Phase III clinical trial results.

Featured In: Clinical Trial News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Reducing Clinical Trial Failure With New Tools for Drug Target Identification and Prioritization


CRO Benchmark Survey: Peer Review and Perspective of Oversight and Collaboration


Agile IRT/RTSM: Enabling Clinical Trial Design and Supply Innovation


Chronic Pain: Conducting Clinical Trials in Osteoarthritis


Copyright © 2016-2017 Honeycomb Worldwide Inc.